ID: ALA541383

Max Phase: Preclinical

Molecular Formula: C23H23Cl2FN4O4S

Molecular Weight: 504.97

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NS(=O)(=O)c2ccc(Cl)cc2F)c(O)c1CC(=O)NCc1ccc(C(=N)N)cc1.Cl

Standard InChI:  InChI=1S/C23H22ClFN4O4S.ClH/c1-13-2-8-19(29-34(32,33)20-9-7-16(24)10-18(20)25)22(31)17(13)11-21(30)28-12-14-3-5-15(6-4-14)23(26)27;/h2-10,29,31H,11-12H2,1H3,(H3,26,27)(H,28,30);1H

Standard InChI Key:  PBIPYPNNELAWHC-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 504.97

Molecular Weight (Monoisotopic): 504.1034

AlogP: 3.44

#Rotatable Bonds: 8

Polar Surface Area: 145.37

Molecular Species: ZWITTERION

HBA: 5

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 6.25

CX Basic pKa: 11.47

CX LogP: 3.51

CX LogD: 3.48

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.18

Np Likeness Score: -1.48

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature